Abstract shows the value of UBC Rapid
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer.
IDL Biotech AB - provides knowledge to decision
IDL Biotech is a diagnostic company that develops, produces, and markets In Vitro Diagnostic (IVD) tests worldwide for the health care sector. We are active in the fields of oncology and bacteriology through manufacturing of various tumor markers and a rapid Salmonella typhoid test. IDL Biotech AB (publ) is a public company listed on the Swedish equities market place, Spotlight Stock Market.
IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.
German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy.
